Guest post by Ylva Hultman, Project Manager Life Science Investments, Stockholm Business Region Development (SBRD)
I work with the Swedish life science sector—aiming to assist and inform corporate investors about business opportunities in the region—with the overall goal to increase investments to that sector. Not saying that the task is easy, I am very privileged to focus on a sector that is viable, under continuous development and stands for a substantial proportion of Sweden’s net export. On a daily basis, I meet companies, investors and decision makers within healthcare and life science and offer advice and practical assistance to companies interested in setting up or expanding business in Stockholm.
In late September for instance, I hosted a session on the Digital Health Days—an international meeting on the intersection between ICT and life science—here in Sweden, and the greater Stockholm region has a lot to offer. From the discussions that followed in the aftermath of that session, it was clear that digital health—including eHealth, mHealth, gaming, etc.—is a highly interesting area for investors focusing on health. However, we also have a long and strong tradition of collaboration between academia and companies generating new knowledge within pharma, biotech and medtech. These industries all strive towards a common goal—patient-centered, safe and cost-effective healthcare.
This is to say that the Stockholm region, in which the Stockholm Business Region Development collaborates with 53 municipalities, is a strong hub for life science R&D. In fact, the region is a virtual unicorn factory, with 5 unicorn companies. This is as many as Berlin has, and well in comparison with San Francisco, a city that can take pride in seven unicorn companies.
Sweden is definitely on the roadmap of life science investors. How about you—will we meet in April for the BIO-Europe Spring® 2016 meeting?